Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

Multiple Sclerosis

Volumn 20, Issue 1, 2014, Pages 43-50

  Axelsson, Markus ^a   Malmeström, Clas ^a   Gunnarsson, Martin ^b,c   Zetterberg, Henrik ^a,d   Sundström, Peter ^e   Lycke, Jan ^a   Svenningsson, Anders ^e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

axonal damage; biomarkers; cerebrospinal fluid; CXCL13; glial fibrillary acidic protein; immunosuppressive therapy; mitoxantrone; Multiple sclerosis; neurofilament light protein; rituximab

Indexed keywords

CXCL13 CHEMOKINE; GADOLINIUM; GLATIRAMER; GLIAL FIBRILLARY ACIDIC PROTEIN; MITOXANTRONE; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTOSIS; AXONAL INJURY; B LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT DURATION; AXONAL DAMAGE; BLOOD BRAIN BARRIER; COHORT ANALYSIS; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PROTEIN CEREBROSPINAL FLUID LEVEL;

AXONAL DAMAGE; BIOMARKERS; CEREBROSPINAL FLUID; CXCL13; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOSUPPRESSIVE THERAPY; MITOXANTRONE; MULTIPLE SCLEROSIS; NEUROFILAMENT LIGHT PROTEIN; RITUXIMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AXONS; BIOLOGICAL MARKERS; CHEMOKINE CXCL13; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROFILAMENT PROTEINS; YOUNG ADULT;

EID: 84890808806     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513490544     Document Type: Article

References (34)

1. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2007 ; 184: 37-44
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993 ; 43: 655-661
3. Buck D, Hemmer B. Treatment of multiple sclerosis: Current concepts and future perspectives. J Neurol. 2011 ; 258: 1747-1762
4. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000 ; 343: 898-904
5. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
6. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology. 2004 ; 63: 1768
7. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998 ; 352: 1491-1497
8. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 ; 61: 14-24
9. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 ; 360: 2018-2025
10. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 ; 66: 460-471
11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
12. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002 ; 59: 679-687
13. Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology. 2004 ; 63: 1788-1795
14. Ceccarelli A, Bakshi R, Neema M. MRI in multiple sclerosis: A review of the current literature. Curr Opin Neurol. 2012 ; 25: 402-409
15. Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012 ; 11: 349-360
16. Daumer M, Neuhaus A, Morrissey S, et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology. 2009 ; 72: 705-711
17. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 ; 69: 83-89
18. Axelsson M, Malmestrom C, Nilsson S, et al. Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis. J Neurol. 2011 ; 258: 882-888
19. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003 ; 61: 1720-1725
20. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007 ; 130: 1089-1104
21. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004 ; 14: 164-174
22. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler. 2011 ; 17: 335-343
23. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009 ; 73: 2003-2010
24. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
25. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
26. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology. 2005 ; 64: 1144-1151
27. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009 ; 73: 1914-1922
28. Norgren N, Sundstrom P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004 ; 63: 1586-1590
29. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of adults. J Neurosci Methods. 1994 ; 51: 197-204
30. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
31. Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998 ; 64: 402-404
32. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 ; 72: 1322-1329
33. Romme Christensen J, Bornsen L, Khademi M, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler. 2012 ;:
34. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: Relation to neurological deficit. J Neurol Sci. 1995 ; 133: 61-65